Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 08 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.62 Insider Own28.46% Shs Outstand26.04M Perf Week-5.92%
Market Cap6.25M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float14.91M Perf Month-19.93%
Income-16.03M PEG- EPS next Q- Inst Own1.23% Short Float / Ratio0.24% / 0.87 Perf Quarter-42.78%
Sales0.24M P/S26.06 EPS this Y- Inst Trans62.37% Short Interest0.04M Perf Half Y-36.28%
Book/sh1.36 P/B0.22 EPS next Y- ROA-38.86% Target Price2.00 Perf Year-69.91%
Cash/sh0.94 P/C0.32 EPS next 5Y- ROE-41.49% 52W Range0.29 - 0.99 Perf YTD-53.23%
Dividend- P/FCF- EPS past 5Y- ROI-56.08% 52W High-69.69% Beta0.71
Dividend %- Quick Ratio10.16 Sales past 5Y1565.19% Gross Margin49.49% 52W Low4.97% ATR0.04
Employees15 Current Ratio10.16 Sales Q/Q-100.00% Oper. Margin-6610.71% RSI (14)42.33 Volatility8.87% 13.70%
OptionableNo Debt/Eq0.01 EPS Q/Q16.85% Profit Margin-6659.90% Rel Volume0.20 Prev Close0.33
ShortableYes LT Debt/Eq0.01 Earnings- Payout- Avg Volume41.13K Price0.30
Recom1.00 SMA20-7.37% SMA50-19.73% SMA200-32.94% Volume8,334 Change-8.87%
Nov-29-23 04:27PM
Nov-09-23 07:59AM
Sep-14-23 08:30AM
Sep-07-23 04:14PM
07:59AM Loading…
Aug-01-23 07:59AM
Jul-31-23 06:00AM
Jul-20-23 08:43AM
Jul-13-23 09:14AM
Jun-30-23 09:28AM
Jun-29-23 02:50PM
Jun-06-23 04:30PM
Jun-05-23 09:00AM
07:57AM Loading…
Jun-01-23 07:57AM
May-14-23 08:13AM
May-03-23 08:26AM
Mar-02-23 08:00AM
Feb-23-23 08:00AM
Feb-16-23 07:30AM
Jan-18-23 08:00AM
Dec-14-22 05:18PM
Dec-12-22 07:00AM
Dec-07-22 04:00PM
Dec-06-22 08:00AM
Nov-28-22 07:05PM
Nov-22-22 04:00PM
Oct-27-22 09:50AM
Oct-17-22 08:00AM
09:48AM Loading…
Oct-14-22 09:48AM
Oct-13-22 04:00PM
Oct-12-22 08:00AM
Oct-10-22 09:39AM
Oct-03-22 06:03PM
Sep-28-22 09:00AM
Sep-20-22 08:00AM
Sep-15-22 08:00AM
Sep-12-22 11:53AM
Sep-09-22 10:32AM
Sep-06-22 09:30AM
Aug-24-22 08:00AM
Aug-18-22 08:00AM
Aug-11-22 08:00AM
Aug-05-22 09:00AM
Aug-02-22 07:00AM
Jul-14-22 08:00AM
Jun-23-22 09:00AM
Jun-22-22 08:00AM
Apr-14-22 04:15PM
Apr-05-22 03:57PM
Mar-30-22 04:15PM
Mar-08-22 08:00AM
Feb-24-22 08:00AM
Feb-09-22 08:00AM
Feb-03-22 08:00AM
Jan-26-22 08:00AM
Dec-23-21 11:35AM
Dec-21-21 08:00AM
Dec-01-21 08:00AM
Nov-29-21 05:45PM
Nov-24-21 08:52AM
Nov-23-21 11:39AM
Nov-17-21 08:00AM
Nov-11-21 08:00AM
Nov-09-21 08:00AM
Oct-27-21 11:40AM
Oct-18-21 01:37PM
Oct-14-21 09:13AM
Oct-11-21 10:08AM
Oct-05-21 08:37AM
Oct-04-21 08:00AM
Sep-29-21 04:30PM
Sep-20-21 12:51PM
Sep-17-21 04:05PM
Pasithea Therapeutics Corp. is a biotechnology company focuses on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine Bendiabdallah and Steinman Lawrence J in May, 2020 and is headquartered in Miami Beach, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STEINMAN LAWRENCEDirectorJun 02Buy0.4330,00012,9301,327,174Jun 06 09:00 PM
Last Close
Dec 08 04:00PM ET
Dollar change
Percentage change
ATNF 180 Life Sciences Corp daily Stock Chart
Index- P/E- EPS (ttm)-14.16 Insider Own6.83% Shs Outstand7.48M Perf Week-15.90%
Market Cap1.78M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float6.96M Perf Month-41.95%
Income-40.45M PEG- EPS next Q- Inst Own9.66% Short Float / Ratio2.29% / 0.34 Perf Quarter-58.02%
Sales0.00M P/S- EPS this Y- Inst Trans- Short Interest0.16M Perf Half Y-80.33%
Book/sh-0.02 P/B- EPS next Y- ROA-205.89% Target Price80.00 Perf Year-96.05%
Cash/sh0.36 P/C0.67 EPS next 5Y- ROE-312.04% 52W Range0.22 - 8.00 Perf YTD-92.98%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-97.02% Beta-
Dividend %- Quick Ratio0.70 Sales past 5Y0.00% Gross Margin- 52W Low5.78% ATR0.06
Employees5 Current Ratio0.70 Sales Q/Q- Oper. Margin0.00% RSI (14)31.24 Volatility19.86% 20.05%
OptionableNo Debt/Eq- EPS Q/Q88.23% Profit Margin- Rel Volume0.64 Prev Close0.24
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume473.26K Price0.24
Recom1.00 SMA20-28.25% SMA50-44.84% SMA200-76.93% Volume302,090 Change-0.79%
Date Action Analyst Rating Change Price Target Change
Sep-15-21Initiated Maxim Group Buy $11
Dec-04-23 09:00AM
Nov-28-23 09:00AM
Aug-14-23 04:29PM
Aug-10-23 08:46AM
Aug-07-23 09:00AM
08:00AM Loading…
Aug-03-23 08:00AM
Jul-31-23 08:00AM
Apr-10-23 04:30PM
Apr-05-23 01:00PM
Feb-27-23 08:30AM
Feb-23-23 07:30AM
Feb-22-23 04:30PM
Jan-25-23 08:45AM
Jan-17-23 08:00AM
Jan-05-23 08:30AM
08:30AM Loading…
Jan-04-23 08:30AM
Dec-29-22 08:30AM
Dec-23-22 08:00AM
Dec-20-22 02:11PM
Dec-16-22 09:00AM
Nov-30-22 05:00PM
Nov-21-22 08:30AM
Nov-15-22 12:37PM
Sep-26-22 08:30AM
Aug-22-22 08:30AM
Jul-27-22 08:30AM
Jul-21-22 08:00AM
Jul-18-22 08:30AM
Jun-22-22 04:05PM
04:15PM Loading…
Jun-14-22 04:15PM
May-31-22 08:30AM
May-02-22 08:00AM
Apr-29-22 06:32PM
Feb-17-22 08:30AM
Jan-31-22 08:00AM
Dec-28-21 11:00AM
Dec-15-21 08:15AM
Dec-12-21 06:06AM
Dec-10-21 05:15PM
Dec-06-21 08:15AM
Dec-01-21 02:45PM
Nov-22-21 08:30AM
Nov-18-21 08:15AM
Nov-03-21 12:06PM
Oct-26-21 08:30AM
Sep-30-21 08:30AM
Sep-20-21 08:00AM
Aug-30-21 08:30AM
Aug-24-21 08:30AM
Aug-19-21 09:00AM
Aug-02-21 08:00AM
Jul-29-21 08:00AM
Jul-28-21 08:15AM
Jul-20-21 08:00AM
Jul-12-21 09:51AM
Jul-07-21 08:00AM
Jun-28-21 08:15AM
Jun-10-21 09:12AM
Jun-01-21 08:00AM
May-28-21 08:00AM
May-21-21 04:45PM
Apr-20-21 08:00AM
Apr-19-21 05:00PM
Apr-14-21 08:15AM
Mar-26-21 08:30AM
Mar-25-21 08:30AM
Mar-24-21 08:30AM
Mar-08-21 01:30PM
Feb-24-21 04:00PM
Feb-19-21 09:00AM
Feb-17-21 12:00AM
Jan-11-21 08:00AM
Jan-05-21 02:50PM
Dec-03-20 11:08AM
Nov-24-20 10:00AM
Nov-23-20 08:30AM
Nov-17-20 08:00AM
Nov-10-20 11:46AM
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STEINMAN LAWRENCEDirectorJun 01Buy1.2318,00022,06848,129Jun 02 08:00 AM
McGovern Jr. Donald A.DirectorMay 31Buy1.1510,00011,47030,099Jun 01 08:00 AM
McGovern Jr. Donald A.DirectorMay 19Buy1.165,0005,80020,099May 22 08:00 AM
Woody James N.Chief Executive OfficerMay 18Buy1.0340,00041,20041,888May 18 04:40 PM
McGovern Jr. Donald A.DirectorMay 18Buy1.0510,00010,50015,099May 22 08:00 AM
Marrone Pamela GDirectorMay 18Buy1.067,0827,50712,469May 19 08:45 AM
Pamir OzanCFOMay 18Buy1.015,1625,2148,983May 19 08:30 AM
Last Close
Dec 08 04:00PM ET
Dollar change
Percentage change
BCAB BioAtla Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-2.65 Insider Own24.43% Shs Outstand46.34M Perf Week-10.17%
Market Cap76.00M Forward P/E- EPS next Y-2.55 Insider Trans0.02% Shs Float36.13M Perf Month-3.64%
Income-124.08M PEG- EPS next Q-0.79 Inst Own58.23% Short Float / Ratio11.41% / 10.12 Perf Quarter-32.63%
Sales0.00M P/S- EPS this Y-0.82% Inst Trans11.61% Short Interest4.12M Perf Half Y-56.44%
Book/sh1.98 P/B0.80 EPS next Y7.81% ROA-72.89% Target Price11.67 Perf Year-83.69%
Cash/sh2.96 P/C0.54 EPS next 5Y- ROE-104.56% 52W Range1.24 - 9.97 Perf YTD-80.73%
Dividend- P/FCF- EPS past 5Y-34.47% ROI-129.31% 52W High-84.05% Beta0.68
Dividend %- Quick Ratio4.14 Sales past 5Y-71.14% Gross Margin- 52W Low28.23% ATR0.17
Employees66 Current Ratio4.14 Sales Q/Q- Oper. Margin0.00% RSI (14)50.22 Volatility13.91% 10.53%
OptionableYes Debt/Eq0.03 EPS Q/Q-1.40% Profit Margin- Rel Volume0.67 Prev Close1.55
ShortableYes LT Debt/Eq0.01 EarningsNov 07 AMC Payout- Avg Volume407.52K Price1.59
Recom1.00 SMA201.99% SMA50-0.91% SMA200-39.18% Volume272,525 Change2.58%
Date Action Analyst Rating Change Price Target Change
Sep-15-22Initiated JMP Securities Mkt Outperform $17
May-05-22Downgrade Credit Suisse Outperform → Neutral $35 → $5
Mar-21-22Initiated H.C. Wainwright Buy $25
Oct-15-21Resumed BTIG Research Buy $68
Jun-28-21Initiated ROTH Capital Buy $75
May-05-21Resumed Credit Suisse Outperform $68
Apr-26-21Resumed Credit Suisse Outperform $68
Jan-11-21Initiated JP Morgan Overweight $45
Jan-11-21Initiated Jefferies Buy $51
Jan-11-21Initiated Credit Suisse Outperform $49
Dec-06-23 08:00AM
Dec-05-23 08:00AM
Nov-30-23 08:00AM
Nov-28-23 08:00AM
Nov-12-23 09:24AM
04:01PM Loading…
Nov-07-23 04:01PM
Nov-06-23 04:05PM
Oct-12-23 07:30AM
Oct-10-23 07:30AM
Sep-06-23 08:00AM
Aug-03-23 04:01PM
Aug-02-23 11:31AM
Aug-01-23 04:01PM
Jul-25-23 08:00AM
07:09AM Loading…
Jul-07-23 07:09AM
Jun-26-23 08:00AM
May-31-23 08:00AM
May-11-23 04:01PM
May-08-23 04:05PM
May-04-23 08:00AM
Apr-29-23 09:29AM
Mar-31-23 06:36AM
Mar-27-23 07:12AM
Mar-24-23 11:31AM
Mar-23-23 04:05PM
Mar-16-23 08:00AM
Feb-27-23 08:07AM
Feb-23-23 08:00AM
Jan-25-23 07:10AM
08:00AM Loading…
Jan-10-23 08:00AM
Dec-29-22 04:05PM
Dec-22-22 08:00AM
Dec-08-22 08:54AM
Dec-01-22 09:55AM
Nov-15-22 09:55AM
Nov-11-22 08:38AM
Nov-08-22 08:00AM
Nov-04-22 11:15AM
Nov-03-22 04:01PM
Oct-27-22 08:00AM
Sep-23-22 09:15AM
Sep-21-22 10:14AM
Sep-12-22 10:08AM
Aug-18-22 06:39AM
Aug-09-22 07:25PM
Aug-03-22 08:00AM
Aug-02-22 08:00AM
Jun-04-22 08:12AM
Jun-01-22 04:05PM
May-04-22 04:01PM
Apr-08-22 08:00AM
Mar-01-22 06:00AM
Feb-07-22 05:38PM
Jan-10-22 04:05PM
Dec-21-21 09:00AM
Dec-11-21 06:34AM
Nov-15-21 05:09PM
Oct-04-21 10:56AM
Sep-29-21 08:03AM
Sep-12-21 08:49AM
Aug-13-21 05:54PM
Jun-14-21 02:03AM
May-12-21 06:26PM
Mar-16-21 01:59AM
Dec-18-20 04:00PM
Dec-16-20 05:34PM
Dec-15-20 07:59PM
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCBRINN SYLVIADirectorSep 08Buy2.542,0005,08011,125Sep 13 06:55 PM
SHORT JAY M PHDChief Executive OfficerMar 29Buy2.4740,800100,8621,412,387Mar 30 07:17 PM
Vasquez ChristianSee RemarksMar 28Buy2.4020,00047,970102,709Mar 29 05:20 PM
MCBRINN SYLVIADirectorDec 19Buy8.333,70030,8139,125Dec 19 05:41 PM